

Springing into action

A warm welcome to this bumper Spring edition of the REVIVED newsletter.

Since the last newsletter we have welcomed two new sites to the REVIVED family. A great big welcome to the teams at Wythenshawe Hospital, Manchester and Ninewells Hospital, Dundee. The Dundee site visit was a great opportunity for some propeller driven travel! There are now 31 sites open and recruiting, and further new sites are expected to open in the coming months.

Recruitment has been fantastic so far in 2018 and there is a focus on how we are meeting our targets on page four of the newsletter.

The Investigators' Meeting, held on the 22nd of March, was a great success. Somehow we managed to fit ten talks into four hours! Thank you to all who contributed to the day, either as an organiser, speaker or attendee. There is a report on the meeting on pages two and three of this newsletter, with the key take home messages below.



Investigators' meeting: Key take home messages



- PCIs should not be performed as treatment for heart failure, except as part of REVIVED
- More angiograms should be performed; currently there is not enough investigation of coronary artery disease nationally
- The most efficient way of identifying patients is to build up a network of engaged colleagues referring potential REVIVED candidates
- REVIVED is an opportunity for the UK to lead in cardiovascular research; the international community are anticipating the results

Contact the REVIVED Clinical Trials Unit at LSHTM

Ruth Canter, Trial Manager
Richard Evans, Senior Manager of the CTU
Jo Astarci, Trial Assistant
Tel: +44 (0)20 7927 2071
Fax: +44 (0)20 7927 2189

Email: revived@LSHTM.ac.uk /
ruth.canter@LSHTM.ac.uk
Website: <http://revived.LSHTM.ac.uk>
Twitter: @REVIVED_BCIS2

Investigators' meeting

A big thank you to the attendees at the REVIVED Investigators' Meeting on 22 March 2018 in London. Fifty-five people attended the meeting, with representatives from 21 different sites.



Divaka Perera

Divaka Perera, the REVIVED Chief Investigator, opened the meeting with a recap of the past year. 2017 was an excellent year for the trial, with confirmation of an extension of recruitment to 30 April 2020. Recruitment was on target with 120 patients. **Ruth Canter**, Trial Manager, also gave an update on the current status of the trial.




Eric Velazquez

Eric Velazquez, Chief of Cardiovascular Medicine at Yale University, gave a fascinating talk on the history of the STICH trial and extension study (STICHES). As with REVIVED, STICH compared medical therapy and revascularisation (CABG instead of PCI) to medical therapy alone. The outcome of the extension study showed a benefit of CABG in longer term survival. Eric also spoke about the importance of REVIVED, and how there are no RCTs in chronic HF to date worldwide, therefore the results of REVIVED are highly anticipated by the international cardiology community.



Mark Petrie

Mark Petrie, PI at Golden Jubilee, highlighted the lack of an evidence base for treatment in patients with heart failure (HF). At the moment there is true equipoise and, as a result, cardiologists should not be performing PCI in HF outside the confines of the trial. REVIVED has the opportunity to fill some of the gaps in knowledge around the role of PCI in HF. There is a lot still to learn about complications of the procedure, such as bleeding, stent thrombosis and vascular complications. The trial will also answer questions about the risk of adverse events in the immediate perioperative period and longer term.




Investigators' meeting



Lana Dixon

We then had talks from staff at three different sites. **Lana Dixon** and **Patricia Glover** spoke on the recent successes at Belfast, with 9 patients recruited in the past 12 months. The team has worked hard to raise awareness about the lack of evidence for PCI and the importance of involving referring hospitals.



Donna Exley, research nurse at Pinderfields, presented on their recent success on REVIVED, with 4 patients in a 6-month period. One clear message from the screening process is the importance of angiograms; if more were done, then recruitment would be easier.

Finally, **Sophie Arnold**, research nurse at St Thomas', gave a talk on maintaining momentum and enthusiasm for the trial. The key is to spread the net wide and make sure the trial remains in people's minds.

Next, **Roshan Weerackody** (Barts) and **Peter O'Kane** (Bournemouth) took us through a series of cases. Peter also talked about the importance of not backing away from complex PCIs; there is always an easy path and a difficult path, but the treatment needs to be what is right for the patient. The overall goal is to maintain focus on REVIVED in order to sustain recruitment.



Peter O'Kane

Lastly, **Tim Clayton**, Associate Professor at LSHTM spoke about why the work of the investigating sites is so critical. Tim spoke about how much had already been achieved, and there were already enough patients to potentially answer some key secondary questions, such as the role of PCI on LV function.

Prize winners



Congratulations to all the sites who won a prize the Investigators' Meeting! Prizes were given to reward recruitment achievements over the past few months



Top recruiters in March

Royal Bournemouth Hospital
Leeds General Infirmary
St Thomas' Hospital

Top recruiters so far in 2018

Barts Heart Centre
Golden Jubilee National Hospital
St Thomas' Hospital

Most recruited in a single month


Barts Heart Centre

Review of the first Quarter of 2018

As winter (technically) comes to an end, we wanted to reflect on what you have done so far this year. We have had a very good start to 2018, with recruitment in both February and March exceeding our overall target of 10.5 patients per month. We are making great progress with each passing month.

We are looking forward to what the spring quarter has in store for REVIVED!

TARGET: 31.5 patients
ACTUAL: 33 patients



Recruitment update

Sites recruited a total of 12 patients in February and 12 patients in March, bringing us to a total of 420 overall. A huge thank you to all the site teams who recruited at least one patient during that period. Our next target is to exceed 450 by the next quarterly review in July. Keep up the great work!

